Visit Capella to learn more about the scientific and clinical progress we and our collaborators are making to advance the field of RNAi.
Leadership in RNAi
These are exciting times for RNAi therapeutics; important scientific and clinical advancements are being made at a very rapid pace. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the belief that this technology has the potential to make a broad and significant impact in medicine is stronger than ever. Alnylam is leading the effort in translating the science of RNAi into a robust drug discovery capability, with the goal of building a sustainable product pipeline of innovative medicines.
At Alnylam, we are unwavering in our commitment to scientific excellence, and we are driven by our dedication to the highest of scientific standards. A testament to this underlying tenet at Alnylam is the publication of our research in world-leading, peer-reviewed scientific journals, such as Nature, Nature Medicine, Nature Biotechnology, and Cell. We believe our numerous publications and collaborations with some of the world's best research labs are important measures of our position as scientific leaders in the RNAi field. Our scientific papers also serve to demonstrate to leading academic scientists, clinicians, and pharmaceutical executives the potential impact of our discoveries and the opportunity for RNAi therapeutics to become a new therapeutic approach in medicine, in addition to Alnylam's commitment to and leadership in translating and advancing the field.